Dr Wainberg has no relationships related to this presentation to disclose
|
|
- Blake Thornton
- 5 years ago
- Views:
Transcription
1 O4 First-in-Human Phase Dose Escalation and Expansion of a Novel Combination, Anti CSF- Receptor (cabiralizumab) Plus Anti PD- (nivolumab), in Patients With Advanced Solid Tumors Zev A. Wainberg, Sarina A. Piha-Paul, Jason Luke, 3 Edward J. Kim, 4 John A. Thompson, 5 Carolyn D. Britten, 6 Jennifer M. Johnson, 7 Nicklas Pfanzelter, 8 Michael Gordon, 9 Drew W. Rasco, F. Stephen Hodi, Amy Weise, Sandeep Inamdar, 3 Serena Perna, 4 Christy Ma, 3 Janine Powers, 3 Yeonju Lee, 3 Majid Ghoddusi, 3 Michael Carleton, 4 Hong Xiang, 3 Lei Zhou, 3 Helen Collins, 3 James J. Lee 5 UCLA Medical Center, Los Angeles, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; 3 University of Chicago Medical Center, Chicago, IL; 4 UC Davis Cancer Center, Sacramento, CA; 5 University of Washington, Seattle Cancer Center, Seattle, WA; 6 Medical University of South Carolina, Charleston, SC; 7 Sidney Kimmel Cancer Center, Jefferson University, Philadelphia, PA; 8 Rush University Medical Center, Chicago, IL; 9 Honor Health Research Institute, Scottsdale, AZ; South Texas Accelerated Research Therapeutics, San Antonio, TX; Dana-Farber Cancer Institute, Boston, MA; Barbara Ann Karmanos Cancer Institute, Detroit, MI; 3 FivePrime Therapeutics, South San Francisco, CA; 4 Bristol-Myers Squibb, Princeton, NJ; 5 University of Pittsburgh Cancer Institute, Pittsburgh, PA
2 FPA8-3 Presenter Disclosures Dr Wainberg has no relationships related to this presentation to disclose Outside the scope of this work, he has received consulting fees from FivePrime and Merck There will be discussion about the use of products for non FDA-approved indications in this presentation
3 FPA8-3 Rationale for Cabiralizumab in Combination With Nivolumab TAM survival Immunosuppressive factors CSF-R CSF- PD-L TAMs inhibit antitumor T-cell activity in the tumor microenvironment, In pancreatic and other cancers, high levels of TAMs are associated with poor prognosis 3-5 Signaling through the CSF- receptor promotes the maintenance and function of TAMs, PD- Tumor survival T-cell function CSF- = colony stimulating factor ; TAM = tumor-associated macrophage; PD- = programmed death-. Ries CH, et al. Cancer Cell 4;5: Cannarile M, et al. J ImmunoTher Cancer 7;5: Hu H, et al. Tumour Biol 6;37: Kurahara H, et al. J Surg Res ;67:e e9. 5. Goswami KK, et al. Cell Immunol 7;36:.
4 FPA8-3 Rationale for Cabiralizumab in Combination With Nivolumab TAM survival Immunosuppressive factors CSF-R Cabiralizumab CSF- PD- PD-L TAMs inhibit antitumor T-cell activity in the tumor microenvironment, In pancreatic and other cancers, high levels of TAMs are associated with poor prognosis 3-5 Signaling through the CSF- receptor promotes the maintenance and function of TAMs, Cabiralizumab is a humanized IgG4 mab that blocks CSF-R 6 and depletes TAMs T cell CSF- = colony stimulating factor ; TAM = tumor-associated macrophage; IgG = immunoglobulin G, mab = monoclonal antibody; PD- = programmed death-. Ries CH, et al. Cancer Cell 4;5: Cannarile M, et al. J ImmunoTher Cancer 7;5: Hu H, et al. Tumour Biol 6;37: Kurahara H, et al. J Surg Res ;67:e e9. 5. Goswami KK, et al. Cell Immunol 7;36:. 6. Bellovin D, et al. Cancer Res 7;77 (3 suppl) [abstract 599]).
5 FPA8-3 Rationale for Cabiralizumab in Combination With Nivolumab TAM survival Immunosuppressive factors CSF-R Restored T-cell function Cabiralizumab CSF- Nivolumab PD- Antitumor response TAMs inhibit antitumor T-cell activity in the tumor microenvironment, In pancreatic and other cancers, high levels of TAMs are associated with poor prognosis 3-5 Signaling through the CSF- receptor promotes the maintenance and function of TAMs, Cabiralizumab is a humanized IgG4 mab that blocks CSF-R 6 and depletes TAMs Preclinical data suggest that CSF-R inhibition synergizes with PD- blockade to enhance antitumor activity 7 CSF- = colony stimulating factor ; TAM = tumor-associated macrophage; IgG = immunoglobulin G, mab = monoclonal antibody; PD- = programmed death-. Ries CH, et al. Cancer Cell 4;5: Cannarile M, et al. J ImmunoTher Cancer 7;5: Hu H, et al. Tumour Biol 6;37: Kurahara H, et al. J Surg Res ;67:e e9. 5. Goswami KK, et al. Cell Immunol 7;36:. 6. Bellovin D, et al. Cancer Res 7;77 (3 suppl) [abstract 599]). 7. Zhu Y, et al. Cancer Res 4;74:
6 FPA8-3 First-in-Human Phase a/b Dose-Escalation Study of Cabiralizumab ± Nivolumab in Advanced Solid Tumors Monotherapy Dose Escalation in Advanced Solid Tumors (n = 4) Cabiralizumab IV QW mg/kg (n = 3) 6 mg/kg (n = ) 4 mg/kg (n = ) Confirm tolerability of 4 mg/kg Combination Dose Escalation in Advanced Solid Tumors (n = ) a Cabiralizumab IV QW Nivolumab IV QW mg/kg + 3 mg/kg (n = 3) mg/kg + 3 mg/kg (n = 4) 6 mg/kg + 3 mg/kg (n = ) 4 mg/kg + 3 mg/kg (n = 3) Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Combination Dose Expansion in Advanced Solid Tumors in Disease-Specific Cohorts (n = 95) Pancreatic cancer (n = 33) Other solid tumors (n = 6) August, 7, cutoff Primary objectives: safety/tolerability, dose-limiting toxicities Secondary objectives: immunogenicity, PK, pharmacodynamics, preliminary antitumor activity b a Initiated after corresponding monotherapy doses were deemed tolerable. b Primary objective for expansion phase IV = intravenous; PK = pharmacokinetics; QW = every weeks 6
7 FPA8-3 Baseline Demographics and Prior Therapy Median age (range), years < 65 years, n (%) Cabiralizumab monotherapy (n = 4) 65.5 (48 88) (4) Cabiralizumab + nivolumab (n = 5) 64 (5 85) (54) Male, n (%) 3 (54) (49) ECOG performance status, n (%) Not reported 7 (9) 7 (7) 55 (7) 45 (7) 4 () (<) No. of prior regimens, n (%) 3 No. of prior regimens for metastatic disease, n (%) 3 ECOG = Eastern Cooperative Oncology Group 5 () (8) 7 (7) 7 (9) 6 (5) 3 (3) 8 (33) 7 (3) 47 (3) 58 (8) 93 (45) 77 (38) 8 (4) 44 () 56 (7) 7
8 FPA8-3 Cabiralizumab serum concentration after first dose (µg/ml) Cabiralizumab Demonstrated Target-Mediated Clearance and Low Immunogenicity Cabiralizumab serum concentration after first dose (µg/ml) Dose escalation (n = 34) Cabira mg/kg + NIVO (n = 4) Cabira 4 mg/kg (n = ) Cabira mg/kg (n = 3) Cabira 4 mg/kg + NIVO (n = 3) Cabira mg/kg + NIVO (n = 3) Cabira 6 mg/kg (n = ) Dose expansion (cabira 4 mg/kg + NIVO 3 mg/kg; pancreatic cohort vs other tumors) Other cancer (n = 56) Pancreatic cancer (n = 33) Day Day Cabiralizumab PK is similar when administered as a monotherapy or in combination with nivolumab PK of cabiralizumab 4 mg/kg QW approaches the linear dose range, suggesting saturation of target-mediated clearance Exposure with the cabiralizumab 4 mg/kg dose in the presence of nivolumab was similar across tumor types Cabiralizumab ± nivolumab demonstrated low immunogenicity (data not shown) Cabira = cabiralizumab; NIVO = nivolumab 8
9 FPA8-3 CD4 + CD6 ++ nonclassical monocytes/µl a in peripheral blood after first dose Cabiralizumab ± Nivolumab Depleted Circulating Monocytes in Patients With Advanced Solid Tumors CD4 + CD6 ++ nonclassical monocytes /µl a in peripheral blood after first dose 8 6 Dose escalation (n = 33) Cabira mg/kg + NIVO (n = 4) Cabira mg/kg (n = 3) Cabira mg/kg + NIVO (n = 3) Cabira 4 mg/kg (n = ) Cabira 4 mg/kg + NIVO (n = 3) Cabira 6 mg/kg (n = ) Dose expansion (cabira 4 mg/kg + NIVO 3 mg/kg; pancreatic cohort vs other tumors) 8 6 Other cancer (n = 43) Pancreatic cancer (n = 3) Day Day Decreases in levels of circulating nonclassical monocytes are a pharmacodynamic marker of cabiralizumab and have been observed with other CSF-R targeting agents -3 Cabiralizumab 4 mg/kg QW was the minimal dose required to consistently deplete circulating nonclassical monocytes throughout the dosing interval; results were similar with cabiralizumab 4 mg/kg + nivolumab Decreases in levels of nonclassical monocytes were similar across tumor types a Bars denote -sided standard deviation. Ries CH, et al. Cancer Cell 4;5: Gomez-Roca CA, et al. J Clin Oncol 5;33(suppl) [abstract 35]. 3. Anthony S, et al. J Clin Oncol ;9(5 suppl) [abstract 393]. 9
10 FPA8-3 Cabiralizumab ± Nivolumab Demonstrated a Tolerable Safety Profile Safety profile of the combination was generally consistent with that of nivolumab, and cabiralizumab 3 monotherapy The most common TRAEs were elevations in creatine kinase and serum liver enzymes (without elevation in bilirubin) These are believed to be secondary to cabiralizumab s depletion of Kupffer cells (macrophages) and were reported with other CSF-R targeting agents 4-6 Isolated enzyme elevations were not associated with other clinical sequelae Cabiralizumab monotherapy (n = 4) Cabiralizumab + nivolumab (n = 5) Any grade, n (%) Grade 3 4, n (%) Any grade, n (%) Grade 3 4, n (%) Any TRAE 5 (63) 3 (54) 84 (9) (49) AEs leading to discontinuation 3 (3) (8) 5 (7) (5) Clinical TRAEs ( 5% of pts treated with combination) Periorbital edema Fatigue Rash Pruritus Nausea Treatment-related laboratory abnormalities of interest Serum enzyme elevations a Pancreatic enzyme elevations b 5 () 7 (9) (4) (8) 3 (3) (4) 3 (3) (4) 9 (38) (8) 84 (4) 74 (36) 38 (9) 34 (7) 3 (5) 3 (5) 4 () Treatment-related deaths 3 (.5) c (<) (5) 8 (4) () 4 () 4 () a Includes AE terms indicative of elevated CPK, AST, ALT, and LDH. b Includes AE terms indicative of elevated amylase and lipase. c Includes pneumonitis in a patient with thyroid cancer (cabiralizumab mg/kg + nivolumab 3 mg/kg), and respiratory distress (n =, cabiralizumab 4 mg/kg + nivolumab) and acute respiratory distress (n =, cabiralizumab 4 mg/kg + nivolumab) in patients with lung cancer. ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; LDH = lactate dehydrogenase; TRAE, treatment-related adverse event. Brahmer J, et al. N Engl J Med 5;373: Ferris RL, et al. N Engl J Med 6;375: Sankhala K, et al. J Clin Oncol 7;35(suppl) [abstract 78]. 4. Ries CH, et al. Cancer Cell 4; 5: Tap WD, et al N Engl J Med 5;373: Papadopoulos KP, et al Clin Cancer Res 7;3:
11 FPA8-3 Cabiralizumab ± Nivolumab Demonstrated a Tolerable Safety Profile Safety profile of the combination was generally consistent with that of nivolumab, and cabiralizumab 3 monotherapy The most common TRAEs were elevations in creatine kinase and serum liver enzymes (without elevation in bilirubin) These are believed to be secondary to cabiralizumab s depletion of Kupffer cells (macrophages) and were reported with other CSF-R targeting agents 4-6 Isolated enzyme elevations were not associated with other clinical sequelae Cabiralizumab monotherapy (n = 4) Cabiralizumab + nivolumab (n = 5) Any grade, n (%) Grade 3 4, n (%) Any grade, n (%) Grade 3 4, n (%) Any TRAE 5 (63) 3 (54) 84 (9) (49) AEs leading to discontinuation 3 (3) (8) 5 (7) (5) Clinical TRAEs ( 5% of pts treated with combination) Periorbital edema Fatigue Rash Pruritus Nausea Treatment-related laboratory abnormalities of interest Serum enzyme elevations a Pancreatic enzyme elevations b 5 () 7 (9) (4) (8) 3 (3) (4) 3 (3) (4) 9 (38) (8) 84 (4) 74 (36) 38 (9) 34 (7) 3 (5) 3 (5) 4 () Treatment-related deaths 3 (.5) c (<) (5) 8 (4) () 4 () 4 () a Includes AE terms indicative of elevated CPK, AST, ALT, and LDH. b Includes AE terms indicative of elevated amylase and lipase. c Includes pneumonitis in a patient with thyroid cancer (cabiralizumab mg/kg + nivolumab 3 mg/kg), and respiratory distress (n =, cabiralizumab 4 mg/kg + nivolumab) and acute respiratory distress (n =, cabiralizumab 4 mg/kg + nivolumab) in patients with lung cancer. ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; LDH = lactate dehydrogenase; TRAE, treatment-related adverse event. Brahmer J, et al. N Engl J Med 5;373: Ferris RL, et al. N Engl J Med 6;375: Sankhala K, et al. J Clin Oncol 7;35(suppl) [abstract 78]. 4. Ries CH, et al. Cancer Cell 4; 5: Tap WD, et al N Engl J Med 5;373: Papadopoulos KP, et al Clin Cancer Res 7;3:
12 FPA8-3 Rationale for Targeting CSF-R in Pancreatic Cancer Pancreatic cancer is associated with high TAM infiltration and poor prognosis, It typically presents as metastatic disease with a -year survival rate of 7%-3% 3 and a 5-year survival rate of %-3% 4,5 Approximately 95%-99% of patients have microsatellite stable (MSS) pancreatic cancer, 6-8 lack response to anti PD-/L therapy, 5,9 and are in need of new treatment options Combination of cabiralizumab and nivolumab may benefit patients with pancreatic cancer by simultaneous reduction of TAMs and inhibition of PD- signaling. Hu H, et al. Tumour Biol 6;37: Kurahara, et al. J Surg Res ;67:e e9. 3. Von Hoff DD, et al. N Engl J Med 3;369: American Cancer Society. Pancreatic cancer. Accessed October, Foley K, et al. Cancer Lett 6;38; Goggins M, et al. Am J Pathol 998; Luttges J, et al. Mod Pathol 3;6: Laghi L, et al. PLOS One ;7:e Brahmer JR, et al. N Engl J Med ;366;
13 FPA8-3 Pancreatic Cancer Cohort Baseline Demographics and Safety Patient demographics and the safety profile in the pancreatic cohort was similar to those in all patients treated with cabiralizumab + nivolumab Baseline demographics and prior therapy Median age (range), years < 65 years, n (%) Cabiralizumab 4 mg/kg + nivolumab 3 mg/kg Pancreatic cancer (n = 33) a 64 (37 85) 7 (5) Male, n (%) 7 (5) ECOG performance status, n (%) No. of prior regimens, n (%) 3 No. of prior regimens for metastatic disease, n (%) 3 3 (39) 9 (58) (3) (3) b 3 (9) 4 (4) 5 (45) 7 () 4 () (36) (3) a Of 33 patients, 3 were response evaluable. b Patient was ineligible or refused standard therapy. 3
14 FPA8-3 Pancreatic Cancer Cohort Baseline Demographics and Safety Patient demographics and the safety profile in the pancreatic cohort was similar to those in all patients treated with cabiralizumab + nivolumab Baseline demographics and prior therapy Median age (range), years < 65 years, n (%) Cabiralizumab 4 mg/kg + nivolumab 3 mg/kg Pancreatic cancer (n = 33) a 64 (37 85) 7 (5) Male, n (%) 7 (5) ECOG performance status, n (%) No. of prior regimens, n (%) 3 No. of prior regimens for metastatic disease, n (%) 3 3 (39) 9 (58) (3) (3) b 3 (9) 4 (4) 5 (45) 7 () 4 () (36) (3) Safety summary Cabiralizumab 4 mg/kg + nivolumab 3 mg/kg Pancreatic cancer (n = 33) a Any grade n (%) Grade 3/4 n (%) Any TRAE 3 (94) (6) AEs leading to discontinuation 3 (9) 3 (9) Clinical TRAEs in 5% of patients Fatigue Periorbital edema Rash Vomiting Hyponatremia Diarrhea Rash maculopapular Treatment-related laboratory abnormalities of interest Serum enzyme elevations c Pancreatic enzyme elevations d 4 (4) (3) 7 () 7 () 6 (8) 5 (5) 5 (5) 7 (5) (6) Treatment-related deaths (3) 3 (9) (3) 3 (9) (33) (3) a Of 33 patients, 3 were response evaluable. b Patient was ineligible or refused standard therapy. c Includes AE terms indicative of elevated CPK, AST, ALT, and LDH. d Includes AE terms indicative of elevated amylase and lipase 4
15 FPA8-3 Deep and Durable Responses Observed in Patients With Pancreatic Cancer Best change in tumor burden over time in efficacy-evaluable patients treated with cabiralizumab 4 mg/kg + nivolumab 3 mg/kg (n = 3) a In this heavily pretreated population, durable clinical benefit was observed in 5 patients (6%) Confirmed ORR = % (Updated confirmed ORR = 3%) Duration of treatment for responders = 75+, 68+, 58, and 47+ days Adjudicated by BIRC as PR All 4 confirmed responses were observed in patients with MSS disease, who historically have not shown benefit with anti PD-/L therapy, Responses were accompanied by steep declines in levels of the pancreatic tumor marker CA9-9 over baseline a Plot shows 3 efficacy-evaluable patients; patients discontinued treatment early due to AEs before disease evaluation. BIRC = blinded independent review committee; ORR = objective 5 response rate; PR = partial response; SLD = sum of longest diameters. Overman M et al. Ann Oncol. 6;7:49-6 [abstract 479P].. Le DT, et al. N Engl J Med 5;37;59 5.
16 FPA8-3 Durable Response in the Liver of a Heavily Pretreated Patient With MSS Pancreatic Cancer Pt A Baseline (October 6) June 7 58-year-old male patient who received 3 prior chemotherapy regimens Neoadjuvant FOLFIRINOX Gemcitabine + nabpaclitaxel 5-FU + leucovorin + liposomal irinotecan Patient achieved a partial response with a best change in tumor burden of 5% CA9-9 levels declined by 99% from baseline Response is ongoing Images provided by James Lee from the University of Pittsburgh Cancer Institute. 5-FU = 5-fluorouracil; FOLFIRINOX = leucovorin + fluorouracil + irinotecan + oxaliplatin 6
17 FPA8-3 Durable Response in the Lung of a Heavily Pretreated Patient With MSS Pancreatic Cancer Pt A Baseline (February 7) July 7 Images provided by Jennifer Johnson from Thomas Jefferson University Hospital. 63-year-old male patient who received 4 prior chemotherapy regimens Adjuvant FOLFIRINOX FOLFIRINOX Capecitabine Gemcitabine + nabpaclitaxel Patient achieved a partial response with a best change in tumor burden of 5% CA9-9 levels declined by 96% from baseline Response is ongoing 7
18 FPA8-3 Conclusions Cabiralizumab is a new immunotherapeutic agent that targets TAMs in the immunosuppressive microenvironment Cabiralizumab with or without nivolumab demonstrated: Tolerable safety profile that is comparable to either monotherapy Dose-dependent reduction of circulating CD4 + CD6 ++ nonclassical monocytes, reaching maximum at 4 mg/kg QW when clearance approaches linear dose range Preliminary evidence of durable clinical benefit with cabiralizumab plus nivolumab was observed in heavily pretreated patients with advanced MSS pancreatic cancer Further cohort expansion is ongoing as well as additional biomarker analyses These data support further study of cabiralizumab plus nivolumab ± chemotherapy in pancreatic cancer (NCT33366) 8
19 FPA8-3 Acknowledgments The patients and families who made this trial possible The clinical study teams who participated in this trial Ago Ahene (FivePrime Therapeutics) for immunogenicity analyses; David Leung (Bristol-Myers Squibb) for assistance with imaging; Urvi Aras (Bristol-Myers Squibb) for review and scientific input FivePrime Therapeutics, Inc. (South San Francisco, CA), Bristol-Myers Squibb (Princeton, NJ), and ONO Pharmaceutical Company, Ltd. (Osaka, Japan) All authors contributed to and approved the presentation; writing and editorial assistance was provided by Jillian Brechbiel of Chrysalis Medical Communications, Inc, funded by Bristol-Myers Squibb 9
More cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationBristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationCorporate Overview. June 2018 NASDAQ:FPRX
Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Antitumor Activity and Safety of FPA144, an ADCCenhanced, FGFR2b Isoform-Selective Monoclonal Antibody, in Patients with FGFR2b + Gastric Cancer and Advanced Solid Tumors Jeeyun Lee 1, Johanna Bendell
More informationPresentation by Dr. Thomas Yau on behalf of his co-authors
4078 First presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Chicago, Illinois, USA, June 3-7, 2016. Reused with permission from the American Society of Clinical Oncology
More informationClinical Activity and Safety of Anti-PD-1 (BMS , MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer
Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer J.R. Brahmer, 1 L. Horn, 2 S.J. Antonia, 3 D. Spigel, 4 L. Gandhi, 5 L.V. Sequist,
More informationICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX /- nivolumab (nivo) in patients with advanced cancers
ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-211 +/- nivolumab (nivo) in patients with advanced cancers Timothy A. Yap 1, Howard A. Burris 2, Shivaani Kummar 3, Gerald
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationCorporate Overview. March 2018 NASDAQ:FPRX
Corporate Overview March 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationPresenter Disclosure Information
Presenter Disclosure Information Tara C. Gangadhar, M.D. The following relationships exist related to this presentation: Research funding (Institution): Incyte Corporation and Merck & Co., Inc Preliminary
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationPresented at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition; December 9 12, 2017; Atlanta, GA, USA
65 Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 25 Study Jonathon B. Cohen, 1 Andreas
More informationPhase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma
Phase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma Abstract #3003 Ribas A, Butler M, Lutzky J, Lawrence D, Robert C, Miller W,
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationOverall Survival (OS) Analysis From an Expanded Access Program (EAP) of Nivolumab (NIVO) in Combination with Ipilimumab (IPI) in Patients with Advanced Melanoma (MEL) David Hogg, Paul B. Chapman, 2 Mario
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationCurrent Affiliation: NEXT Oncology, San Antonio TX
Safety, Efficacy, and Immune Correlates of Alternative Doses and Schedules of Entinostat Combined With Pembrolizumab in Patients With Advanced Solid Tumors Results From SNDX-275-0141 Phase I Trial Anthony
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationTGFβR1 Kinase Inhibitor
TGFβR1 Kinase Inhibitor Galunisertib, LY2157299 H 2 0 Prud homme GJ 1 ; Flavell RA, et al 2 Drug Discovery Platform: Cancer Angiogenesis and Tumor Microenvironment/Immuno-Oncology A Phase 1b/2 Dose-Escalation
More informationAnti-CD27 Agonist Antibody Varlilumab with Nivolumab for Colorectal and Ovarian Cancer: Phase 1/2 Clinical Trial Results
Anti-CD27 Agonist Antibody Varlilumab with Nivolumab for Colorectal and Ovarian Cancer: Phase 1/2 Clinical Trial Results 1, Michael J. Pishvaian 2, Margaret K. Callahan 3, Amy Weise 4, Branimir I. Sikic
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationNivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142
Nivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142 Abstract #519 Overman MJ, Lonardi S, Leone F, McDermott
More informationONT-380 and HER2+ Breast Cancer
ONT-380 and HER2+ Breast Cancer Diana F. Hausman, MD CMO, VP Clinical Development Oncothyreon Inc. PNW Bio February 10 2015 Copyright 2014 Copyright Oncothyreon 2014 Oncothyreon Oncothyreon Leading Oncology
More informationClinicalTrials.gov Identifier: NCT Adi Diab 1, Nizar Tannir 1, Daniel Cho
Pivot-02: Preliminary safety, efficacy and biomarker results from dose escalation of the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic melanoma,
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationSingle Agent Activity of ZW25, a HER2-Targeted Bispecific Antibody, in Heavily Pretreated HER2-Expressing Cancers
Single Agent Activity of ZW25, a HER2-Targeted Bispecific Antibody, in Heavily Pretreated HER2-Expressing Cancers 1, Murali Beeram 2, Jose Mayordomo 3, Diana Hanna 4, Jaffer Ajani 1, Mariela Blum Murphy
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationCorporate Overview. September 2018 NASDAQ:FPRX
Corporate Overview September 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationQ Financial Update November 6, 2018 NASDAQ:FPRX
Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,
More informationAttached from the following page is the press release made by BMS for your information.
June 2, 2015 Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb s PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma (PRINCETON,
More informationU.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma Application includes CheckMate -066,
More informationAll Patients N=38 Complete response mg/kg q2w. 1 mg/kg q2w. 6 mg/kg q3w n=10. All Patients N= mg/kg. 10 mg/kg. q3w n=10.
58P Phase /, Open-Label, Multiple Ascending Dose Trial of AGEN34, an Anti PD- Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation in Advanced Cancer and Expansion Cohorts in
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationMy name is Dr. David Ilson, Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, New York.
Welcome to this CME/CE-certified activity entitled, Integrating the Latest Advances Into Clinical Experience: Data and Expert Insights From the 2016 Meeting on Gastrointestinal Cancers in San Francisco.
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationNKTR-214 (CD-122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT
NKTR-214 (CD-122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT ClinicalTrials.gov Identifier: NCT02983045 Adi Diab 1, Michael Hurwitz 2,
More informationTGFβR1 Kinase Inhibitor
TGFβR1 Kinase Inhibitor Galunisertib, LY2157299 H 2 0 Derived from Prud homme GJ 1 ; Flavell RA, et al. 2 Drug Discovery Platform: Cancer Angiogenesis and Tumor Microenvironment/Immuno-Oncology A Phase
More informationEfficacy of larotrectinib in adolescents and young adults with TRK fusion cancer
Efficacy of larotrectinib in adolescents and young adults with TRK fusion cancer Soledad Gallego, 1 Valentina Boni, 2 Ulrik Lassen, 3 Anna Farago, 4 Wafik El-Deiry, 5 David Hong, 6 Blanca López-Ibor, 2
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationAuthor Block M. Fisch, J. W. Lee, J. Manola, L. Wagner, V. Chang, P. Gilman, K. Lear, L. Baez, C. Cleeland University of Texas M.D. Anderson Cancer Ce
Survey of disease and treatment-related t t related symptoms in outpatients with invasive i cancer of the breast, prostate, lung, or colon/rectum (E2Z02, the SOAPP study, Abst # 9619) Michael J. Fisch,
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationCorporate Overview. June 2017 NASDAQ:FPRX
Corporate Overview June 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationAttached from the following page is the press release made by BMS for your information.
September 28, 2015 Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma (PRINCETON,
More informationASCO Annual Meeting 2013, May 31 June , Chicago, IL
Phase I Study of Safety and Pharmacokinetics of GDC-0917, an Antagonist of Inhibitor of Apoptosis Proteins in Patients with Refractory Solid Tumors or Lymphoma 1 A Tolcher, 1 K Papadopoulos, 1 A Patnaik,
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationIl Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali
Il Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali Lorenza Rimassa Medical Oncology Unit Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Disclosures
More informationClinical Development for Patients with Cancer
OMP 59R5: a Novel Therapeutic Antibody in Clinical Development for Patients with Cancer Jakob Dupont, MD, MA Chief Medical Officer and Senior Vice President OncoMed Pharmaceuticals Inc. Adjunct Clinical
More informationDurable Responses Observed in Recurrent High Grade Glioma (rhgg) with Toca 511 & Toca FC Treatment
Durable Responses Observed in Recurrent High Grade Glioma (rhgg) with Toca 511 & Toca FC Treatment Cloughesy TF 1, Landolfi J 2, Vogelbaum MA 3, Ostertag D 4, Elder JB 5, Bloomfield S 2, Carter B 6, Chen
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationEmerging Strategies in Triple-Negative Breast Cancer
Expert Review in Immunotherapy in Breast Cancer Emerging Strategies in Triple-Negative Breast Cancer Reference Slide Deck Is Breast Cancer Immunogenic? Recent proof that breast cancer may elicit an immune
More informationMay 31, NCCN Guidelines: T-Cell Lymphomas
May 31, 2017 Maria Rivas, MD Senior Vice-President Global Medical Affairs Merck & Co. Kenilworth - Galloping Hill, +1 908 740 6533 K6-1624G maria.rivas1@merck.com NCCN Guidelines: T-Cell Lymphomas On behalf
More informationU.S. Food and Drug Administration Accepts Supplemental Biologics License Application. for Opdivo (nivolumab)
September 3, 2015 U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients (PRINCETON,
More information2019 ASCO-SITC. Nektar Therapeutics Investor & Analyst Call. March 1, 2019
Nektar Therapeutics Investor & Analyst Call March 1, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of
More informationOMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationDana-Farber Cancer Institute, Boston, MA, USA; 2. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 3
The investigational agent MLN9708, an oral proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationCheckpoint-Inhibitoren beim Lungenkarzinom. Dr. Helge Bischoff Thoraxklinik Heidelberg
Checkpoint-Inhibitoren beim Lungenkarzinom Dr. Helge Bischoff Thoraxklinik Heidelberg Survival (%) First-Line: Polychemotherapy vs 9387 patients 778 patients in studies with platinum chemotherapy 1-year
More informationBreast Cancer Immunotherapy. Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy
Breast Cancer Immunotherapy Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy Conflict of Interest I have the following financial relationships to disclose:
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More information79956F Kitano et al_bi754091bi TiP_JSMO 2018 (NB).pdf 1 13/07/ :55:06 C M Y CM MY CY CMY K
79956F Kitano et al_bi754091bi754111 TiP_JSMO 2018 (NB).pdf 1 13/07/2018 13:55:06 C M Y CM MY CY CMY K Phase 1 trial of an anti-pd-1 mab BI 754091 ± an anti-lag-3 mab BI 754111 in Asian patients with advanced
More informationChallenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies
Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies David Feltquate MD, PhD Head of Early Clinical Development, Oncology Bristol-Myers Squibb, Princeton, NJ Challenges
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationPresenter Disclosure Information
Monotherapy Dose Escalation Clinical and Translational Data from the First-in-Human Study in Advanced Solid Tumors of IPI-549, an Oral, Selective PI3K-γ Inhibitor Targeting Tumor Macrophages David S. Hong,
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationAttached from the following page is the press release made by BMS for your information.
September 17, 2015 Bristol-Myers Squibb s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Renal Cell Carcinoma (PRINCETON, NJ, September
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationDisclosures Information Brendan D. Curti, MD
The MITCI (Phase 1b) study: A novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationSan Antonio Breast Cancer Symposium December 5-9, 2017
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, as 3rd-line Therapeutic Option for Patients With Relapsed/Refractory Metastatic Triple-Negative Breast Cancer (mtnbc): Efficacy
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationAttached from the following page is the press release made by BMS for your information.
June 22, 2015 European Commission Approves Bristol-Myers Squibb s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced
More informationDevelopment of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More information